No wonder they released this RNS in the quiet period - Very difficult to take any positives from it -
Injectables deal not done
Loan at desperation interest rates and subject to conditions that truss them up like a turkey - seems like a Paul Capital deal without the benefit of the shared risk.
Fluti costs at double the previously anticipated level.
Fluti licencees not covering manufacturing cap ex.
In all very disapointing which I think will be reflected in the sp when the market catches up
Scpie stock quotes
Scpie stock charts
Follow this thread
